China-US biopharma, Cellular Biomedicine recently announced a $30.6 million investment from Shanghai-Hong Kong PE investor, Sailing Capital Overseas. As part of the transaction, Sailing will appoint a representative to the Company’s Board of Directors. Cantor Fitzgerald & Co. acted as a financial advisor to the company.

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. CBMG conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. CBMG GMP facilities in China, consist of twelve independent cell production lines, and are designed and managed according to both China and U.S. GMP standards.

Sailing’s investment in CBMG further validates their proprietary technology platform and independently affirms the prospects for CFDA approval and commercialization in China.

CBMG’s Shanghai facility includes a Joint Laboratory of Cell Therapy with GE Healthcare and a Joint Cell Therapy Technology Innovation and Application Center with Thermo Fisher Scientific. CBMG currently has ongoing CAR-T Phase I clinical trials in China; CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL) and CALL-1 for adult Acute Lymphoblastic Leukemia (ALL), utilizing CBMG’s proprietary and optimized CD19 construct.